BBC Russian

DRUG: Saxagliptin and dapagliflozin

Entry

D10826            Mixture   Drug

Name

Saxagliptin and dapagliflozin;
Qtern (TN)

Product

QTERN (AstraZeneca Pharmaceuticals LP)

Component

(Saxagliptin [DR:D08996] | Saxagliptin hydrate [DR:D09753] | Saxagliptin hydrochloride [DR:D10262]), (Dapagliflozin [DR:D08897] | Dapagliflozin propanediol [DR:D09763])

Class

Antidiabetic agent
DG02044 Hypoglycemic agent
DG03035 Combination of DPP-4 inhibitor and SGLT2 inhibitor

Remark

ATC code:

A10BD21

Product:

D10826<US>

Efficacy

Antidiabetic

Disease

Type 2 diabetes mellitus [DS:H00409]

Interaction

Brite

Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
A ALIMENTARY TRACT AND METABOLISM
  A10 DRUGS USED IN DIABETES
   A10B BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
    A10BD Combinations of oral blood glucose lowering drugs
     A10BD21 Saxagliptin and dapagliflozin
      D10826  Saxagliptin and dapagliflozin <US>
USP drug classification [BR:br08302]
Blood Glucose Regulators
  Antidiabetic Combinations
   Dapagliflozin/ Saxagliptin
    D10826  Saxagliptin and dapagliflozin
Drug groups [BR:br08330]
Antidiabetic agent
  DG02044  Hypoglycemic agent
   DG03035  Combination of DPP-4 inhibitor and SGLT2 inhibitor
    D10826  Saxagliptin and dapagliflozin
Drug classes [BR:br08332]
Antidiabetic agent
  DG02044  Hypoglycemic agent
   D10826  Saxagliptin and dapagliflozin
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
  D10826

Other DBs

PubChem:

319902626

LinkDB

» Japanese version » Back

DBGET integrated database retrieval system